Should You Buy Genmab A/S (GMAB) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
BUY now for a long-term beginner investor. The stock just sold off (~-4.3% regular session) into a technically meaningful support zone (between S1 ~31.48 and pivot ~33.22) while the longer-term trend remains constructive (SMA_5 > SMA_20 > SMA_200). Fundamentals are strong (2025/Q3 revenue +25% YoY, EPS +121% YoY), options positioning is strongly call-skewed (very low put/call ratios), and 2026 is described by analysts as catalyst-rich. Near-term momentum is weak (negative, expanding MACD histogram), but for an impatient long-term buyer, the current pullback is a reasonable entry rather than waiting for a perfect setup.
Technical Analysis
Trend/momentum: Despite the sharp one-day drop, the moving average stack is bullish (SMA_5 > SMA_20 > SMA_200), indicating the broader trend is still up. However, momentum has turned bearish short-term: MACD histogram is negative (-0.0574) and expanding lower, consistent with ongoing downside pressure. RSI(6)=45.5 is neutral, suggesting the stock is not oversold yet and could still be volatile. Levels: Pivot 33.22 is overhead (now acting as near-term resistance after the close at 32.81). First support is S1 31.48 (key level to hold); deeper support S2 30.41. Upside resistance levels are ~34.96 (R1) then ~36.03 (R2). Practical read: price is below pivot but not far from support, making risk/reward acceptable for a long-term entry after the pullback.
